IASO BioMed (IASO) 10-Q 19 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 15, 2019
Document And Entity Information
Entity Registrant Name	IASO BioMed, Inc.
Entity Central Index Key	0001662907
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,248,744
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash	$ 11,100	$ 140,234
Prepaid expenses	4,522	1,451
Total current assets	15,622	141,685
TOTAL ASSETS	15,622	141,685
CURRENT LIABILITIES:
Accounts payable	150,633	92,901
Accounts payable, related party	70,000	43,000
Note payable, related party	60,000	60,000
Accrued salaries	515,000	402,500
Accrued board fees	170,000	140,000
Accrued interest, related party	7,589	5,803
Total current liabilities	973,222	744,204
TOTAL LIABILITIES	973,222	744,204
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' DEFICIT:
Preferred stock, $.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $.0001 par value, 100,000,00 shares authorized; 37,248,744 and 35,952,632 shares issued and outstanding	3,725	3,595
Additional paid-in capital	2,437,432	2,435,051
Accumulated deficit	(3,398,757)	(3,041,165)
Total shareholders' deficit	(957,600)	(602,519)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 15,622	$ 141,685

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ .0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, Shares outstanding
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,248,744	35,952,632
Common stock, shares outstanding	37,248,744	35,952,632

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues
Operating expenses:
General and administrative	151,035	104,793	288,806	645,150
Professional and consulting expense, related party	15,000	15,000	32,000	20,000
Research and development		75,000	35,000	85,000
Total operating expenses	166,035	194,793	355,806	750,150
Loss From Operations	(166,035)	(194,793)	(355,806)	(750,150)
Other Expenses:
Interest expense, related party	898	898	1,786	1,786
Total other expenses	898	898	1,786	1,786
Net Loss	$ (166,933)	$ (195,691)	$ (357,592)	$ (751,936)
Earnings per Common Share:
Basic and diluted loss per share	$ 0.01	$ (0.01)	$ (0.01)	$ (0.02)
Weighted average number of common Shares outstanding:
Basic and diluted	37,248,744	34,922,412	37,149,134	34,726,113

Condensed Statement of Stockhol

Condensed Statement of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 3,425	$ 1,108,126	$ (1,403,928)	$ (292,377)
Balance, shares at Dec. 31, 2017	33,252,632
Sale of common stock	$ 25	99,975		100,000
Sale of common stock, shares	250,000
Warrant exercises	$ 43	4,207		4,250
Warrant exercises, shares	425,000
Share-based compensation		357,428		357,428
Net loss			(751,936)	(751,936)
Balance at Jun. 30, 2018	$ 3,493	1,569,736	(2,155,864)	(582,635)
Balance, shares at Jun. 30, 2018	33,927,632
Balance at Mar. 31, 2018	$ 3,490	1,569,489	(1,960,173)	(387,194)
Balance, shares at Mar. 31, 2018	34,902,632
Warrant exercises	$ 3	247		250
Warrant exercises, shares	25,000
Net loss			(195,691)	(195,691)
Balance at Jun. 30, 2018	$ 3,493	1,569,736	(2,155,864)	(582,635)
Balance, shares at Jun. 30, 2018	33,927,632
Balance at Dec. 31, 2018	$ 3,595	2,435,051	(3,041,165)	(602,519)
Balance, shares at Dec. 31, 2018	35,952,632
Warrant exercises	$ 130	2,381		2,511
Warrant exercises, shares	1,296,112
Share-based compensation
Net loss			(357,592)	(357,592)
Balance at Jun. 30, 2019	$ 3,725	2,437,432	(3,398,757)	(957,600)
Balance, shares at Jun. 30, 2019	37,248,744
Balance at Mar. 31, 2019	$ 3,725	2,437,432	(3,231,824)	(790,667)
Balance, shares at Mar. 31, 2019	37,248,744
Net loss			(166,933)	(166,933)
Balance at Jun. 30, 2019	$ 3,725	$ 2,437,432	$ (3,398,757)	$ (957,600)
Balance, shares at Jun. 30, 2019	37,248,744

Condensed Statement of Cash Flo

Condensed Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows from Operating Activities:
Net loss	$ (357,592)	$ (751,936)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		357,428
Changes in assets and liabilities:
Prepaid expenses	(3,071)	(2,792)
Accounts payable	84,732	64,760
Accrued salaries	112,500	112,500
Accrued board fees	30,000	120,000
Accrued interest, related party	1,786	1,786
Net cash used in operating activities	(131,645)	(98,254)
Cash Flows from Financing Activities:
Proceeds from sale of common stock		100,000
Proceeds from the exercise of warrants	2,511	4,250
Net cash provided by financing activities	2,511	104,250
Net Increase (Decrease) in Cash	(129,134)	5,996
Cash, beginning of period	140,234	20,191
Cash, end of period	$ 11,100	$ 26,187

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	1. Nature of Operations and Summary of Significant Accounting Policies Nature of Operations rd Basis of presentation In the opinion of management, all adjustments (consisting only of normal recurring adjustments) which are necessary to provide a fair presentation of operating results for the interim periods presented have been made. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the year. Reclassification Cash and Cash Equivalents Use of Estimates Research and Development Costs Share-based Compensation The Company uses the Black-Scholes option-pricing model to estimate the fair value of warrants and the market price of our common stock, or comparable public companies if our stock is not trading, on the date of grant for the fair value. Our determination of fair value of share-based awards is affected by those stock prices as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate. Income Taxes Fair Value of Financial Instruments Earning (Loss) Per Share Recently Issued Accounting Pronouncements Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending September 30, 2019 and interim periods within that annual period. Early adoption is permitted. The Company does not expect ASU 2017-09 will have a significant impact on its financial statements upon adoption.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. Going Concern At June 30, 2019 and December 31, 2018, the Company had cash of $11,100 and $140,234, respectively. It also had a working capital deficit of $957,600 and $602,519, respectively and an accumulated deficit of $3,398,757 and $3,041,165, respectively. This raises substantial doubt about the Company’s ability to continue as a going concern. Management is taking action to ensure the Company will continue as a going concern for at least one year beyond the date of the issuance of the Company’s financial statements. From March 11, 2015 (Inception) through June 30, 2019, the Company sold $971,842 in common stock. Common stock sales continue pursuant to private placement and other potential equity offerings. These fundraising efforts may not be successful. While there can be no assurances, management believes that these actions will enable the Company to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	3. Related Party Transactions Note Payable In October 2017, the Company executed an unsecured promissory note to Richard Schell for $35,000 bearing interest at 6% per annum, which remained outstanding at June 30, 2019 and December 31, 2018 with accrued interest payable of $3,647 and $2,606, respectively. A total of $1,786 of interest expense was accrued during each of the six-month periods ended June 30, 2019 and 2018, respectively. Employment Agreements In March 2017 the Company entered into an employment agreement with its CFO for a two-year term, which term was extended by our board of directors in January 2019 for an additional two-year term until March 2021. The CFO will assume his responsibilities on a part time basis until requested by the Board of Directors to become a full-time executive. The base salary of $75,000 per annum is payable to the CFO only upon the Company’s raising of an additional $750,000. When the CFO becomes a full-time executive, his salary will be increased to $125,000 per annum. The CFO also received warrants to purchase 500,000 shares of the Company’s common stock at $0.40 per share for a period of five years after issuance. 250,000 warrants vested upon signing the agreement and the remaining 250,000 vested in March 2018. The CFO will also be eligible to earn discretionary annual performance bonuses upon meeting certain objectives as determined by the Board of Directors, none of which have been granted to date. The agreement provides for severance payments. The Company accrued $112,500 in salaries related to these agreements in each of the six-month periods ended June 30, 2019 and 2018, respectively. Scientific Advisory Board Agreements Also, effective March 1, 2018, we entered into a Scientific Advisory Board Agreement with our director Dr. Karatzas (the “Karatzas Agreement”), through which Dr. Karatzas agreed to serve on our Scientific Advisory Board. The term of the Karatzas Agreement is one year from execution and may be renewed annually by mutual consent of both parties. The Karatzas Agreement provides for payments as follows: an annual fee of $25,000; a signing bonus of $50,000 payable after successful closing of any cumulative minimum $1,000,000 investment in the Company; a non-discretionary bonus of $40,000 payable following a successful financing round of a minimum of $2,000,000; and should the Karatzas Agreement be renewed after one year, a $90,000 bonus payable only after the signing bonus and non-discretionary bonus from year one have been earned. In order to receive the non-discretionary bonus payments Dr. Karatzas must be actively involved in the creation and execution of strategies necessary for the Company to achieve its strategic plan including the scientific, commercial and business objectives, as applicable and as agreed upon between the Dr. Karatzas and the Company’s Chief Executive Officer. In January 2019, this agreement was extended for an additional year under the same terms and conditions and will expire in February 2020. The Company accrued a total of $30,000 in fees related to these agreements for the six-month period ended June 30, 2019 and accrued $120,000 in fees related to these agreements in the six-month period ended June 30, 2018, which included $20,000 in fees and $100,000 in signing bonuses. Services Agreement he Company pays the Company’s Corporate Secretary’s company $400 per month for reimbursement of certain administrative charges such as computer, internet, phone and similar items. The agreement is on a month-to-month basis and may be terminated at any time by either party. Total expense for the six-months ended June 30, 2019 and 2018 was $2,400. Consulting Agreement and Other Payments Effective March 1, 2018, the Company entered into a Consulting Agreement with our Corporate Secretary through which he will be paid $5,000 per month for a term of two years and is automatically extended on an annual basis unless terminated by either party with thirty days written notice. A total of $30,000 and $20,000 was accrued under this agreement in the six-month periods ended June 30, 2019 and 2018, respectively. In addition, we paid a total of $2,000 to a company controlled by our Corporate Secretary for additional consulting services rendered during the six-month period ended June 30, 2019. Warrants In October 2018, our board of directors issued our corporate secretary a warrant to purchase up to 211,112 shares of our common stock for a period of three months at an exercise price of $0.001 per share. These warrants were exercised in January 2019. These warrants were determined by the Company to have a fair market value of $84,236 using the Black-Scholes option pricing model.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Stockholders' Equity	4. Stockholders’ Equity The Company has the authority to issue 110,000,000 shares of $.0001 par value stock, of which 100,000,000 shares are common stock and 10,000,000 shares are preferred stock. As of June 30, 2019, and December 31, 2018 there were 37,248,744 and 35,952,632 common stock shares issued and outstanding. For the six-month period ended June 30, 2018, the Company sold $100,000 in its private placement, issuing 250,000 shares of our common stock at $0.40 per share that included warrants to purchase up to 250,000 shares of our common stock exercisable at $0.75 per share for a period of three years from issuance. During the six-month period ended June 30, 2018, the Company issued warrants to purchase up to 860,000 shares of common stock at an exercise price of $0.01 per share to business, legal and scientific consultants; 400,000 of which were to expire in December 2022 and 460,000 of which expire in February 2021. Subsequent to issuance, 425,000 of these warrants were exercised for proceeds to the Company of $4,250. We incurred stock compensation expense totaling $336,926 in connection with the issuance of these warrants as more fully explained in Note 6 – Share-based Compensation. On November 1, 2018, the Registrant’s Board approved the issuance of warrants to purchase shares of the Company’s common stock to two of its executive officers. Mr. Duane C. Knight, Chief Financial Officer of the Registrant, received a warrant to purchase up to 950,000 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. Mr. Thomas B. Olson, Corporate Secretary of the Registrant, received a warrant to purchase up to 211,112 shares of common stock exercisable for period of three months at an exercise price of $0.001 per share. Messrs. Knight and Olson exercised these warrants in January 2019 for total proceeds to the company of $1,161. In January 2019 we issued 135,000 shares upon the exercise of warrants to purchase 135,000 shares issued in September and October 2018 at an exercise price of $0.01 per share for total proceeds to the Company of $1,350.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Royalties ● CAD $5,000 on the issuance of the first US patent that accrued US$3,750 in the first quarter of 2019 ● CAD $25,000 on the filing of an investigational new drug application or regulatory filing ● CAD $50,000 on the initiation of the first Phase II clinical study ● CAD $100,000 on the initiation of the first Phase III clinical study ● CAD $300,000 on receipt of regulatory approval The Company must also pay milestone payments as follows for the out of body test to identify Alzheimer’s disease as follows: ● CAD $5,000 on the issuance of the first US patent ● CAD $50,000 on the filing of a 510(k) or PMA application ● CAD $200,000 on receipt of regulatory approval In addition, the Company issued 5% of the total number of issued and outstanding shares in the Company’s Series A financing to the same institution, or 1,652,632 shares in March 2016. This agreement, payable in Canadian dollars, exposes the Company to foreign exchange transaction gains and losses. In August 2016, the Company issued an additional 300,000 shares of the Company’s common stock to McGill in lieu of the pre-existing anti-dilution provision. As McGill owns more than 5% of the Company’s outstanding common stock, it is considered a related party. Research Agreement Scientific Advisory Board

Share-based Compensation

Share-based Compensation	6 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Share-based Compensation	6. Share-based Compensation In March 2017, the Company issued 750,000 warrants to the Company’s officers to purchase shares of our common stock at $0.40 per share. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 1.55 % Expected term 3 years Volatility 154 % Dividend yield - Fair value $ 0.33 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to these warrants was $20,502 for the six-months ended June 30, 2018. In February and March 2018, the Company issued warrants to purchase up to 860,000 shares of common stock at an exercise price of $0.01 per share to business, legal and scientific consultants; 400,000 of which were to expire in December 2022 and 460,000 of which expire in February 2021. Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 2.33 – 2.34 % Expected term 2.5 years Volatility 182 – 217 % Dividend yield - Fair value $ 0.39 Expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company’s historical stock warrant exercise experience does not provide a reasonable basis upon which to estimate expected term. As such, the simplified method was used to calculate the expected term. The Company calculated volatility based on the volatilities of comparable public companies. Total share-based compensation related to these warrants was $336,926 for the six months ended June 30, 2018. We incurred no share-based compensation in the six-month period ended June 30, 2019.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	7. Subsequent Events Management has determined that there are no further events subsequent to the balance sheet date that should be disclosed in these financial statements. In July and August 2019 we issued notes payable to our president, Richard Schell, together totaling $9,000, which are due on demand and carry an interest rate of 6% per annum.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations rd
Basis of Presentation	Basis of presentation In the opinion of management, all adjustments (consisting only of normal recurring adjustments) which are necessary to provide a fair presentation of operating results for the interim periods presented have been made. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the year.
Reclassification	Reclassification
Cash and Cash Equivalents	Cash and Cash Equivalents
Use of Estimates	Use of Estimates
Research and Development Costs	Research and Development Costs
Share-based Compensation	Share-based Compensation The Company uses the Black-Scholes option-pricing model to estimate the fair value of warrants and the market price of our common stock, or comparable public companies if our stock is not trading, on the date of grant for the fair value. Our determination of fair value of share-based awards is affected by those stock prices as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
Income Taxes	Income Taxes
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Earning (Loss) Per Share	Earning (Loss) Per Share
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Leases In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period ending September 30, 2019 and interim periods within that annual period. Early adoption is permitted. The Company does not expect ASU 2017-09 will have a significant impact on its financial statements upon adoption.

Share-based Compensation (Table

Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Estimated Fair values of Warrants Granted Using the Black-Scholes Option Pricing Model	Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 1.55 % Expected term 3 years Volatility 154 % Dividend yield - Fair value $ 0.33 Estimated fair values of warrants granted were determined using the Black-Scholes option pricing model with the following average assumptions: Risk-free interest rate 2.33 – 2.34 % Expected term 2.5 years Volatility 182 – 217 % Dividend yield - Fair value $ 0.39

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Accounting Policies [Abstract]
Research and development costs		$ 75,000	$ 35,000	$ 85,000
Antidilutive securities excluded from computation of earnings per share, amount			11,100,000	9,595,000

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	52 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 11,100	$ 140,234
Working capital deficit	957,600	602,519
Accumulated deficit	(3,398,757)	$ (3,041,165)
Sold common stock, value	$ 971,842

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)

Mar. 01, 2018

Jan. 02, 2017

Oct. 31, 2018

Mar. 31, 2018

Mar. 31, 2017

Jun. 30, 2019

Jun. 30, 2018

Jun. 30, 2019

Jun. 30, 2018

Jan. 31, 2019

Dec. 31, 2018

Jul. 02, 2018

Oct. 31, 2017

Oct. 31, 2016

Related Party Transaction [Line Items]

Interest expense

$ 898

$ 898

$ 1,786

$ 1,786

Warrants to purchase common stock

250,000

250,000

425,000

Warrants [Member]

Related Party Transaction [Line Items]

Warrants to purchase common stock

135,000

Papadopoulos Agreement [Member]

Related Party Transaction [Line Items]

Annual fees

$ 35,000

$ 20,000

Amount awarded to serve as scientific advisory board

10,000

Signing bonus payable on closing of cumulative minimum investment

50,000

100,000

Cumulative minimum investment

1,000,000

Non-discretionary bonus

45,000

Financing round of minimum payment

2,000,000

Bonus payable

95,000

Accrued fees

30,000

120,000

Karatzas Agreement [Member]

Related Party Transaction [Line Items]

Annual fees

25,000

Signing bonus payable on closing of cumulative minimum investment

50,000

Cumulative minimum investment

1,000,000

Non-discretionary bonus

40,000

Financing round of minimum payment

2,000,000

Bonus payable

90,000

Services Agreement [Member]

Related Party Transaction [Line Items]

Reimbursement charges per month

$ 400

Reimbursement expense

2,400

2,400

Consulting Agreement and Other Payments [Member]

Related Party Transaction [Line Items]

Accrued fees

30,000

20,000

Agreement related fees

$ 5,000

5,000

Additional consulting services fee paid

2,000

Richard Schell, CEO [Member]

Related Party Transaction [Line Items]

Note payable, related party

$ 25,000

Notes payable, bearing interest percentage

6.00%

Accrued interest payable

3,941

3,941

$ 3,197

Richard Schell, CEO [Member] | Employment Agreement [Member]

Related Party Transaction [Line Items]

Agreement term

2 years

Base salary

$ 150,000

Additional capital to be raised as target

$ 750,000

Warrants to purchase common stock

250,000

Warrants, exercise price

$ 0.40

Warrants term

5 years

Richard Schell, CEO [Member] | Employment Agreement [Member] | Warrants [Member]

Related Party Transaction [Line Items]

Warrants, vested

125,000

125,000

Richard Schell, CEO [Member] | Unsecured Promissory Note [Member]

Related Party Transaction [Line Items]

Note payable, related party

$ 35,000

Notes payable, bearing interest percentage

6.00%

Accrued interest payable

$ 3,647

3,647

$ 2,606

CFO [Member]

Related Party Transaction [Line Items]

Warrants to purchase common stock

950,000

Warrants, exercise price

$ .001

Warrants fair market value

$ 379,062

CFO [Member] | Employment Agreement [Member]

Related Party Transaction [Line Items]

Agreement term

2 years

Base salary

$ 75,000

Additional capital to be raised as target

$ 750,000

Warrants to purchase common stock

500,000

Warrants, exercise price

$ 0.40

Warrants term

5 years

Increase salary per annum

$ 125,000

CFO [Member] | Employment Agreement [Member] | Warrants [Member]

Related Party Transaction [Line Items]

Warrants, vested

250,000

250,000

CEO and CFO [Member] | Employment Agreement [Member]

Related Party Transaction [Line Items]

Compensation expenses

$ 112,500

$ 112,500

Board of Directors [Member]

Related Party Transaction [Line Items]

Warrants to purchase common stock

211,112

Warrants, exercise price

$ 0.001

Warrants fair market value

$ 84,236

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Jul. 02, 2018	Jan. 31, 2019	Oct. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Nov. 01, 2018	Mar. 31, 2018	Feb. 28, 2018
Class of Stock [Line Items]
Number of shares authorized to issue				110,000,000		110,000,000
Common stock, par value				$ 0.0001		$ 0.0001
Common stock, shares authorized				100,000,000		100,000,000
Preferred stock, shares authorized				10,000,000		10,000,000
Common stock, shares issued				37,248,744		35,952,632
Common stock, shares outstanding				37,248,744		35,952,632
Stock price per share					$ 0.40
Warrants issued to purchase common stock	425,000				250,000
Warrants exercise price					$ 0.75
Proceeds from the exercise of warrants	$ 4,250			$ 2,511	$ 4,250
Stock compensation expense					$ 336,926
Business, Legal and Scientific Consultants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock								860,000	860,000
Warrants exercise price								$ 0.01	$ 0.01
Stock compensation expense				$ 336,926
Mr. Duane C. Knight [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock							950,000
Warrants exercise price							$ 0.001
Warrants term period							3 months
Mr. Thomas B. Olson [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock							211,112
Warrants exercise price							$ 0.001
Warrants term period							3 months
Mr. Duane C. Knight and Mr. Thomas B. Olson [Member]
Class of Stock [Line Items]
Proceeds from the exercise of warrants		$ 1,161
Warrants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock		135,000
Warrants exercise price			$ 0.01
Proceeds from the exercise of warrants			$ 1,350
Warrants exercised			135,000
Warrants [Member] | Business, Legal and Scientific Consultants [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock					860,000
Warrants exercise price					$ 0.01
Warrants [Member] | Business, Legal and Scientific Consultants [Member] | December 2022 [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock					400,000
Warrants expiration date					Dec. 31, 2022
Warrants [Member] | Business, Legal and Scientific Consultants [Member] | February 2021 [Member]
Class of Stock [Line Items]
Warrants issued to purchase common stock					460,000
Warrants expiration date					Feb. 28, 2021
Private Placement [Member]
Class of Stock [Line Items]
Proceeds from issuance of stock through private placements					$ 100,000
Issuance of common stock					250,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)

1 Months Ended

3 Months Ended

6 Months Ended

Apr. 30, 2019USD ($)

Mar. 31, 2019shares

Sep. 30, 2018USD ($)$ / sharesshares

Jun. 30, 2018USD ($)$ / sharesshares

Mar. 31, 2017USD ($)

Aug. 31, 2016shares

Jan. 31, 2016USD ($)

Jan. 31, 2016CAD ($)

Jun. 30, 2019USD ($)

Jun. 30, 2018USD ($)$ / sharesshares

Jun. 30, 2019USD ($)

Jun. 30, 2018USD ($)$ / sharesshares

Jul. 02, 2018shares

Mar. 31, 2016shares

Jan. 31, 2016CAD ($)

Loss Contingencies [Line Items]

Research and development

$ 75,000

$ 35,000

$ 85,000

Warrants issued to purchase common stock | shares

250,000

250,000

250,000

425,000

Warrants exercise price | $ / shares

$ 0.75

$ 0.75

$ 0.75

Research Institute of the McGill University Health Centre [Member]

Loss Contingencies [Line Items]

Research and development

$ 35,000

Four New Member Scientific Advisory Board [Member]

Loss Contingencies [Line Items]

Warrants issued to purchase common stock | shares

35,000

Warrants exercise price | $ / shares

$ 0.01

Paid annual fee

$ 25,000

Warrants exercised | shares

35,000

Amount of expense related to agreements

$ 50,000

Research Agreement [Member]

Loss Contingencies [Line Items]

Research and development

$ 65,000

$ 130,000

$ 130,000

Agreement term

1 year

1 year

1 year

Agreement term, description

The Company paid these installment payments in July and October 2017 leaving no balance due

McGill [Member]

Loss Contingencies [Line Items]

Additional issuance of common stock | shares

300,000

Equity method investment, ownership percentage

5.00%

Series A financing [Member]

Loss Contingencies [Line Items]

Percentage of issued and outstanding shares issued as milestone payments

5.00%

Common stock shares issued for milestone payment | shares

1,652,632

CAD Currency [Member]

Loss Contingencies [Line Items]

Annual royalty expense

$ 5,000

Royalty [Member]

Loss Contingencies [Line Items]

Annual revenue from royalty, percentage

3.00%

3.00%

Androgen Replacement Treatment [Member] | First US Patent [Member]

Loss Contingencies [Line Items]

Accrued milestone payments

$ 3,750

Androgen Replacement Treatment [Member] | CAD Currency [Member] | First US Patent [Member]

Loss Contingencies [Line Items]

Milestone payments for treatment

$ 5,000

Androgen Replacement Treatment [Member] | CAD Currency [Member] | Investigational New Drug Application or Regulatory Filing [Member]

Loss Contingencies [Line Items]

Milestone payments for treatment

25,000

Androgen Replacement Treatment [Member] | CAD Currency [Member] | First Phase II Clinical Study [Member]

Loss Contingencies [Line Items]

Milestone payments for treatment

50,000

Androgen Replacement Treatment [Member] | CAD Currency [Member] | First Phase III Clinical Study [Member]

Loss Contingencies [Line Items]

Milestone payments for treatment

100,000

Androgen Replacement Treatment [Member] | CAD Currency [Member] | Receipt of Regulatory Approval [Member]

Loss Contingencies [Line Items]

Milestone payments for treatment

300,000

Alzheimer Disease [Member] | CAD Currency [Member] | First US Patent [Member]

Loss Contingencies [Line Items]

Milestone payments for treatment

5,000

Alzheimer Disease [Member] | CAD Currency [Member] | Receipt of Regulatory Approval [Member]

Loss Contingencies [Line Items]

Milestone payments for treatment

200,000

Alzheimer Disease [Member] | CAD Currency [Member] | Filing of a 510(K) or PMA Application [Member]

Loss Contingencies [Line Items]

Milestone payments for treatment

$ 50,000

Share-based Compensation (Detai

Share-based Compensation (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jul. 02, 2018	Mar. 31, 2018	Feb. 28, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued to purchase common stock		250,000	425,000
Warrants exercise price		$ 0.75
Share-based compensation		$ 336,926
December 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued to purchase common stock				400,000	400,000
Warrant expired date				Dec. 31, 2022	Dec. 31, 2022
February 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued to purchase common stock				460,000	460,000
Warrant expired date				Feb. 28, 2021	Feb. 28, 2021
Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued to purchase common stock						750,000
Warrants exercise price						$ 0.40
Share-based compensation		$ 20,502
Business, Legal and Scientific Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued to purchase common stock				860,000	860,000
Warrants exercise price				$ 0.01	$ 0.01
Share-based compensation	$ 336,926

Share-based Compensation - Sche

Share-based Compensation - Schedule of Estimated Fair values of Warrants Granted Using the Black-Scholes Option Pricing Model (Details) - $ / shares	1 Months Ended	2 Months Ended
	Mar. 31, 2017	Feb. 28, 2018
Warrant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.55%
Expected term	3 years
Volatility rate	154.00%
Dividend yield	0.00%
Fair value	$ 0.33
Warrant Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate, minimum		2.33%
Risk free interest rate, maximum		2.34%
Expected term		2 years 6 months
Volatility rate, minimum		182.00%
Volatility rate, maximum		217.00%
Dividend yield		0.00%
Fair value		$ 0.39

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - Richard Schell [Member]	Aug. 31, 2019USD ($)
Notes payable	$ 9,000
Interest rate	6.00%